Multivariate analyses for overall survival (OV), disease-free survival (DFS), and progression-free survival (PFS) suggested that high expression of POU2F1 was associated with decreased OS, DFS, and PFS of GC patients in TCGA-STAD cohort (P=0.004, P=0.0055, and P=0.00077, respectively; Figure 2(c)). This evidence concerns the gene POU2F1 and gastric cancer.